Cadila Healthcare has received final USFDA approval to market blood pressure drug, Tiadylt ER. The drug diltiazem hydrochloride (Tiadylt ER) extended release capsules will be available in multiple strengths of 120mg, 180mg, 240mg, 300mg and 420mg and will be manufactured at the groups formulations manufacturing facility at pharma SEZ in Ahmedabad. Besides blood pressure, the drug diltiazem hydrochloride is also prescribed for angina and certain heart rhythm disorders. It may be noted, the company also final approval from the US FDA to market azelastine hydrochloride 137 mcg nasal pray, which is used in treatment of runny nose, sneezing and post nasal drip caused by allergies.
Company Profile : Cadila Healthcare Ltd
Leave a Reply